论文部分内容阅读
目的：探讨巴曲酶（ｂａｔｒｏｘｏｂｉｎ）可否治疗缺血性脑血管疾病（ＩＣＶＤ）及其安全性。方法：随机选择，并经ＣＴ及（或）ＭＲＩ证实的急性ＩＣＶＤ３８例，男性２３例，女性１５例，年龄６５±ｓ１０ａ，用巴曲酶溶于１００ｍＬ生理盐水中静脉滴注，首次剂量１０ＢＵ，维持剂量５ＢＵ，隔日１次，１个疗程共３次。结果：４ｗｋ显效率５３％，总有效率８４％，作用迅速，用药后７２ｈ内出现疗效者８７％，同时使血清凝血因子１显著降低，交链纤维蛋白降解物显著增高。治疗期间未发现任何不良反应。结论：巴曲酶是一种新型强力单成分溶栓剂，治疗急性ＩＣＶＤ安全可行。
Objective: To investigate whether batroxobin can treat ischemic cerebrovascular disease (ICVD) and its safety. Methods: A total of 38 cases of acute ICVD were randomly selected and confirmed by CT and / or MRI. There were 23 males and 15 females, aged 65 ± s10a. Batroxobin was dissolved in 100 mL of normal saline intravenously. The first dose of 10BU, To maintain the dose 5BU, every other day 1, a course of 3 times. Results: 4wk markedly effective rate of 53%, the total effective rate of 84%, the role of rapid, 72h after treatment appeared 87% of the effect, while the serum coagulation factor 1 significantly reduced cross-linked fibrin degradation was significantly increased. During the treatment did not find any adverse reactions. Conclusion: Batroxobin is a new and powerful single-component thrombolytic agent, which is safe and feasible for the treatment of acute ICVD.